Clinical trials: Glaucoma
Compliance
Compliance With Once Daily Glaucoma Medication
A study to examine patient compliance with once daily glaucoma medication
- Trial name
- NCT00333463
- Testing
- Intervention
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Alcon Research
Pediatric Glaucoma, Elevated IOP in Pediatric Patients
Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients
The purpose of this study is to evaluate the intraocular pressure (IOP)-lowering efficacy of Travoprost 0.004% POLYQUAD (PQ) ophthalmic solution compared to Timolol ophthalmic solution (0.5% or 0.25%) in pediatric glaucoma…
- Conditions
- Pediatric Glaucoma, Elevated IOP in Pediatric Patients, Ocular Hypertension in Pediatric Patients
- Trial name
- NCT01652664
- Testing
- Travoprost 0.004% PQ ophthalmic solution, Timolol, 0.5% or 0.25% ophthalmic solution, Travoprost Vehicle
- Volunteers
- 184 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma
Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort
The purpose of this study is to assess the long-term safety of the Glaukos® iStent® Trabecular Micro-Bypass Stent Model GTS100R/L in subjects previously enrolled in Glaukos Study GC-003.
- Trial name
- NCT01836042
- Where
- 26 sites in United States
- Volunteers
- 108 people
- Sponsor
- Glaukos Corporation
Glaucoma, Open-Angle
iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval Study
Long term follow up of subjects in the IDE study for iStent Inject to monitor safety
- Trial name
- NCT04624685
- Where
- 24 sites in United States
- Volunteers
- 475 people
- Sponsor
- Glaukos Corporation
Glaucoma, Open-Angle
A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System
The purpose of this study is to evaluate the long-term safety and effectiveness of the OMNI® Surgical System in subjects who were treated under protocol #06213
- Trial name
- NCT05044793
- Testing
- OMNI® Surgical System
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- Sight Sciences, Inc.
Glaucoma, Ocular Hypertension
Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients
The purpose of this study was to assess the safety and describe the steady-state plasma pharmacokinetic (PK) profiles of Travoprost ophthalmic solution, 0.004% (new formulation) following a once daily administration for 7 days in…
- Trial name
- NCT01658839
- Testing
- Travoprost ophthalmic solution, 0.004% (new formulation)
- Volunteers
- 25 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle
An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)
The purpose of this study is to evaluate the safety and effectiveness of the OMNI® Surgical System in subjects who have undergone canaloplasty and trabeculotomy using OMNI® Surgical System without any concomitant surgery in…
- Trial name
- NCT04872348
- Testing
- OMNI® Surgical System
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Sight Sciences, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Intraocular Pressure (IOP) Reduction in Newly Diagnosed Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study and will evaluate IOP reduction in newly diagnosed patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians…
- Trial name
- NCT01628614
- Testing
- Standard of Care
- Where
- Spain
- Volunteers
- 4,812 people
- Sponsor
- Allergan
Open-angle Glaucoma (OAG), Ocular Hypertension (OHT)
Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients
Qlaris Phase 2 clinical study investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in combination with latanoprost in open-angle glaucoma (OAG) and/or ocular hypertension (OHT) patients.
- Conditions
- Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma
- Trial name
- NCT06249152
- Testing
- QLS-111, 0.015%, QLS-111, 0.030%, QLS-111, 0.075%
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Qlaris Bio, Inc.
Open Angle Glaucoma, Ocular Hypertension
Evaluation of Safety and Efficacy of PDP-716
The study will be conducted to evaluate the efficacy and safety of topical administration of PDP-716 compared with brimonidine tartrate ophthalmic solution.
- Trial name
- NCT03450629
- Testing
- Brimonidine Tartrate Ophthalmic Suspension, Brimonidine Tartrate Ophthalmic Solution
- Where
- 47 sites in United States
- Volunteers
- 682 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
- Trial name
- NCT01632423
- Testing
- bimatoprost 0.01%
- Where
- Germany
- Volunteers
- 10,337 people
- Sponsor
- Allergan
Glaucoma, Ocular Hypertension
Survey of Patients Taking IOP-Lowering Eye Drops
Survey to assess perspectives of patients prescribed IOP-lowering eye drops at a single office visit.
- Trial name
- NCT02384772
- Testing
- Survey
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- ForSight Vision5, Inc.
Glaucoma
5 Years Long Term Results After Standalone CyPass-Implantation
This study evaluates the results of all clinically relevant findings of glaucoma diagnostics 5 Years after stent-implantation concerning the safety and effectiveness of the cypass stent procedure.
- Trial name
- NCT03114059
- Testing
- Glaucoma diagnostics
- Where
- Germany
- Volunteers
- 230 people
- Sponsor
- Dietrich-Bonhoeffer-Klinikum
Glaucoma, Ocular Hypertension
A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension
The purpose of the study is to examine how preservative free tafluprost ophthalmic solution (0.0015%) is distributed in blood circulation after ocular administration in children who have glaucoma or elevated intraocular pressure.
- Trial name
- NCT02102750
- Testing
- Preservative free tafluprost opthalmic solution
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 17 people
- Sponsor
- Santen Oy
Glaucoma and Ocular Hypertension
A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study
This is a Phase III, randomized, double-masked, active-controlled, parallel-group, multi-center study. Subjects diagnosed with glaucoma or OHT who meet eligibility criteria at Visit 1 (Screening) will washout of their current…
- Trial name
- NCT03691662
- Testing
- DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
- Where
- 34 sites in United States
- Volunteers
- 417 people
- Sponsor
- Santen Inc.
Primary Open-angle Glaucoma
Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry
The purpose of this study is to observe the safety of the Glaukos® iStent® Trabecular Micro-Bypass Stent Model GTS100 in conjunction with cataract surgery in subjects with mild to moderate open-angle glaucoma.
- Trial name
- NCT01841437
- Testing
- iStent
- Where
- 18 sites in United States
- Volunteers
- 191 people
- Sponsor
- Glaukos Corporation
Sturge-Weber Syndrome, Glaucoma
Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)
Open-label study of an investigational product (IP), QLS-101, with 28-day every morning (QAM) dosing to both eyes (OU) in adolescents with SWS who have clinical evidence of glaucoma and/or ocular hypertension (OHT) related to SWS…
- Conditions
- Sturge-Weber Syndrome, Glaucoma, Ocular Hypertension
- Trial name
- NCT05495269
- Testing
- QLS-101 ophthalmic solution, 2.0 %
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Qlaris Bio, Inc.
Glaucoma, Ocular Hypertension
Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension
The objective of this Investigation is to evaluate the safety and efficacy of long-term treatment with Xalacom in medical practice.
- Trial name
- NCT01191008
- Testing
- Latanoprost-timolol maleate fixed combination ophthalmic solution
- Volunteers
- 661 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Ocular Hypertension
Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom
Non-interventional study to obtain real life data from the treatment with Xalatan and Xalacom in Germany and to assess the long-term efficacy and tolerability under routine conditions.
- Trial name
- XCHANGE (NCT01012245)
- Testing
- no intervention
- Volunteers
- 28,812 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open-Angle Glaucoma, Ocular Hypertension
Study of TRAVATAN in Subjects With Iris Pigmentation Changes
The purpose of this study was to monitor iris pigmentation changes over a 5-year period in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00047554
- Testing
- Travoprost, 0.004% ophthalmic solution
- Volunteers
- 336 people
- Sponsor
- Alcon Research